The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
After finishing at $33.06 in the prior trading day, Spyre Therapeutics Inc (NASDAQ: SYRE) closed at $33.47, up 1.24%. In other words, the price has increased by $1.24 from its previous closing price. On the day, 0.63 million shares were traded. SYRE stock price reached its highest trading level at $34.24 during the session, while it also had its lowest trading level at $32.88.
Ratios:
Our goal is to gain a better understanding of SYRE by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.90 and its Current Ratio is at 10.90. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Mizuho on December 18, 2025, initiated with a Outperform rating and assigned the stock a target price of $53.
On December 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $64.
On September 26, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $43.Deutsche Bank initiated its Buy rating on September 26, 2025, with a $43 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 01 ’25 when Turtle Cameron sold 15,000 shares for $29.02 per share. The transaction valued at 435,356 led to the insider holds 686,907 shares of the business.
Turtle Cameron sold 45,000 shares of SYRE for $1,049,778 on Nov 03 ’25. The Chief Executive Officer now owns 701,907 shares after completing the transaction at $23.33 per share. On Nov 03 ’25, another insider, CAMERON TURTLE, who serves as the Director of the company, bought 90,000 shares for $24.46 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SYRE now has a Market Capitalization of 2597008640 and an Enterprise Value of 2266630656.
Stock Price History:
The Beta on a monthly basis for SYRE is 3.14, which has changed by 0.38558257 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, SYRE has reached a high of $35.31, while it has fallen to a 52-week low of $10.91. The 50-Day Moving Average of the stock is 27.79%, while the 200-Day Moving Average is calculated to be 80.99%.
Shares Statistics:
The stock has traded on average 919.09K shares per day over the past 3-months and 770100 shares per day over the last 10 days, according to various share statistics. A total of 77.59M shares are outstanding, with a floating share count of 67.52M. Insiders hold about 12.99% of the company’s shares, while institutions hold 77.00% stake in the company. Shares short for SYRE as of 1764288000 were 11157711 with a Short Ratio of 12.14, compared to 1761868800 on 12407305. Therefore, it implies a Short% of Shares Outstanding of 11157711 and a Short% of Float of 17.37.
Earnings Estimates
. The current rating of Spyre Therapeutics Inc (SYRE) is the result of assessments by 11.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.69, with high estimates of -$0.49 and low estimates of -$0.92.
Analysts are recommending an EPS of between -$0.98 and -$3.37 for the fiscal current year, implying an average EPS of -$2.14. EPS for the following year is -$2.78, with 11.0 analysts recommending between -$0.75 and -$4.55.
